Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Flunixin
Bimeda Chemicals
QM01AG90
Flunixin
50 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle, Horses
flunixin
N.S.A.I.D.
Authorised
1996-02-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin Injection 50 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM A clear, colourless solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and horses. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES CATTLE: For the control of acute inflammation associated with respiratory disease. Cronyxin Injection may be used as adjunctive therapy in the treatment of acute mastitis. HORSES: For the alleviation of inflammation and pain associated with musculoskeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic. 4.3 CONTRAINDICATIONS Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity. Each ml contains: ACTIVE SUBSTANCE: Flunixin (as Flunixin Meglumine) 50.0 mg EXCIPIENTS: Phenol Ph.Eur. 5.0 mg Sodium formaldehyde sulfoxylate 2.2 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _0_ _7_ _/_ _0_ _1_ _/_ _2_ _0_ _1_ _6_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _2_ _5_ _9_ _0_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4 Read the complete document